Abstract
We report a case of a child presenting with sub-acute cerebellar ataxia that was associated with anti- N-methyl-D- aspartate (NMDA) receptor antibodies who dramatically responded to early aggressive immunomodulating therapy but not to conventional therapy. A three-year-old boy with history of prematurity and speech delays presented with subacute onset ataxia followed by progression to choreoathetosis, dysphagia, oro-facial dyskinesia, insomnia, aggressive behavior and loss of speech. An extensive work up for causes of ataxia and occult malignancy was negative except for presence of oligoclonal bands and anti-NMDA receptor antibodies in the cerebrospinal fluid. The patient did not improve despite treatment with steroids and intravenous immunoglobulin. His first improvement occurred within 48 hr of rituximab infusion and with continued rituximab he returned to his neurological baseline. This anti-NMDA receptor encephalitis case presented as cerebellar ataxia refractory to conventional treatment and responded to rituximab.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call